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ABSTRACT 
Cancer is one of the leading causes of death.  There have been many investigations into therapeutic 
ways to prevent and reverse cancerous growth.  We report a  new approach in this thesis, which is to  
investigate the functions of Vitamin B1 (thiamine) in cancerous cells and their  regulation.  A number of 
thiamine analogs were synthesized to carry out the structure-activity relationship (SAR) studies with two 
transporters THTR1 and THTR2.  Initial results show that the modifications of thiazole reduced the 
uptake of thiamine. 
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1 INTRODUCTION 
 
1.1 Cancer, an important target 
  
 Cancer is one of the most common causes of among Americans, second only to heart disease.  
The expected number of newly diagnosed cancer cases in 2012 will be 1,638,910in the US alone. 1  Out 
of the 1.6 million expected cases, approximately 577,190 Americans are expected to die from their 
respective cancers.1  Cancer occurs when cells divide out of control, forming a tumor. In a rapidly 
growing tumor, cells will eventually outrun their blood supply, leading to hypoxia, low pH, and lack of 
nutrients.  Under these conditions, the cancer cells must adapt in order to maintain their growth rate 
and survival.  The cells must induce angiogenesis, glycolysis, and limitless division and become 
metastatic.  The processes that cancer cells utilize to perform these tasks are not well understood. 
Research must therefore be carried out to learn more about these processes, and eventually find 
acceptable solutions to treating cancer patients  
 
1.2 Hypoxia Induciable Factor (HIF-1) 
A key component that aids cancer cells in maintaining their cell functions is a protein called 
hypoxia inducible factor (HIF-1).2  HIF-1 is a heterodimer that is composed of two subunits (HIF-1α and 
HIF-1β).3  Under normal cell conditions, HIF-1α is degraded. Under hypoxic conditions, it accumulates  
and combines with HIF-1β to form the HIF-1 protein complex that turns on transcription of genes 
involved in glycolysis and angiogenesis,  functions that are important to tumor growth and survival.4,5  
Growth and survival are essential to cells in general, regardless of whether or not they are cancerous. 
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There are numerous networks in the body that are used jointly to supply energy.  One particular 
pathway, the pentose phosphate pathway (PPP), is exploited by cancerous cells, and is crucial for nucleic 
acid synthesis and production of NADPH for biosynthetic pathways.6 
The concentration of HIF-1α is dependent on the intracellular concentration of oxygen.  Under 
normal conditions, HIF-1α is constantly degraded via ubiquitination and proteosomal degradation.  The 
degradation is facilitated by the oxygen dependent enzyme prolyl hydroxylase.  The co-substrates of the 
enzyme are iron and 2-oxoglutarate, which is used to hydroxylate the specific amino acid residue.7  Once 
hydroxylation occurs, HIF-1α binds to the Von Hippel-Lindau protein, which marks for protosomal 
degradation.4, 7c  Under hypoxic conditions, however, HIF-1α stabilizes, accumulates, and translocates to 
the nucleus, where it binds to HIF-1β to form the active transcription factor, HIF-1.4, 7c 
 
Figure 1:  Schematic description of how of the HIF-1 protein is formed and degrade.8 
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 PPP is also known as the phosphogluconate pathway or hexose monophosphate shunt.  This 
pathway is part of an interconnected network for energy production.  The pathway contains two phases.  
The first phase is an oxidative phase wherein NADPH is generated.  Second is the non-oxidative phase, 
where a ribose is synthesized.  In the non-oxidative portion of the pathway, two specific enzymes known 
as transketolase and transaldolase are utilized to catalyze a series of reactions that convert three 
pentoses into 2 hexoses and one triose.  More specifically, transketolase contains thiamine and it serves 
as an electron sink, where it stabilizes the intermediates.  Thus, the importance of thiamine cannot be 
understated.  
A 
Nonoxidative phase Oxidative phase
Glucose-6-phosphate
NADP+
NADPH
6-Phosphogluconate
NADP+
NADPHCO2
Ribulose-5-phosphate
Ribose-5-phosphate
Nucleotides, coenzyme
DNA, RNA
Transketolase
transaldolase
Fatty acids
sterols, etc.
Precursors
2GSH
GSSH
Glutathione
reductase
reductive
biosynthesis
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B 
C5 + C5 C3 + C7
C7 + C3 C3 + C7
C5 + C4 C3 + C6
transketolase
transaldolase
transketolase
 
Figure 2:  A)  General scheme of the pentose phosphate pathway.  B)  Reactions involved in PPP, the 
non-oxidative pathway, converting two pentoses into two hexoses, one triose and two NADPH. 
 
1.3 Thiamine 
 Thiamine is a colorless compound with an aminopyrimidine ring and a thiazole ring as a core 
structure.  It was the first water-soluble vitamin to be discovered and described in 1888 by Kanehiro 
Takaki; however, the biological functions were not  fully understood, until 1958.6  Thiamine cannot be 
synthesized in the body, and must therefore be obtained from food or dietary supplements.  Thiamine 
enters the body through the intestinal track and gets metabolized in cells where it gets phosphorylated 
by thiamine pyrophosphokinase-1 (TPK-1) to become thiamine mono-phosphate (TMP) and thiamine 
pyrophosphate (TPP).  Once thiamine is in the body, it gets transported into the cell through two 
transport proteins: THTR1 and THTR2.  Within the glycolytic network, thiamine is an essential cofactor 
for three different enzymes.  The first enzyme is the pyruvate dehydrogenase (PDH) complex in the 
Embden-Meyerhof (EM) pathway, which has the purpose of converting pyruvate into acetyl CoA.  The 
second enzyme is the α-ketoglutarate dehydrogenase (α-KGDH) in the Kreb’s cycle, which has the 
function of converting α-ketoglutarate into succinyl CoA.9  The last enzyme that thiamine acts as a 
cofactor for is transketolase (TK) in the pentose phosphate pathway (PPP).  Under hypoxic conditions, 
however, it has been shown to reduce PDH and α-KGDH10 activities, while TK activity has been shown to 
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increase.11   The role of thiamine in the cell is essential because of its roles in energy production and the 
synthesis of anabolic precursors for biosynthesis.12  In the pentose phosphate pathway, thiamine is an 
important cofactor for the enzyme transketolase,12b, 13which in turn is responsible for the synthesis of 
approximately 85% of the C5-ribose sugars for nucleic acid synthesis.6  Therefore, it is essential to 
investigate on how thiamine can regulate what?  
N
N
NH2
N+
S OH 
Figure 3:  Structure of thiamine, which contains theaminopyrimidine and thiazole motifs.  
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Figure 4:  Reaction scheme of thiamine pyrophosphate inside the active site of transketolase.9  
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Figure 5:  Structure of thiamine pyrophosphate (TPP), the active form in the enzyme transketolase. 
 Thiamine deficiency leads to beriberi.14  The disease is divided into two major categories: wet 
beriberi and dry beriberi.  Wet beriberi affects the cardiovascular system, causing dilation of blood 
vessel, and eventually leading to edema.15  Edema may result in chest pain due to over pumping of the 
heart.  Wernicke-Korsakoff syndrome is also known as dry beriberi and is caused by thiamine deficiency.  
Wernicke's  characteristics  are oculomoter abnormalities and cognitive impairment.16  Occurrences in 
US are rare due to consumption of food with high thiamine content. Beriberi usually occurs more often 
in individuals who abuse alcohol, which can prevent the body from properly absorbing and storing 
thiamine. 
 
1.5 Purpose of this study 
 It is known that proliferation of cancer cells increases as the supplementation of thiamine 
increases.17  However, several questions remain.  Hypoxic cancer cells have been shown to utilize the 
pentose phosphate pathway by increasing the inactive dimer of pyruvate kinase to shuttle glycolytic 
intermediate into the pathway.18  Therefore, it is important to understand this process and to use this 
knowledge to develop therapeutic targets.   The purpose of this study is to understand how cancer cells 
maintain homeostasis thiamine concentration to maintain thiamine-dependent enzyme activity.  The 
determination of how thiamine transporters are regulated will help the understanding of how thiamine 
is important to cancer cells. Functionality and structural features of the thiamine transporters THTR1 
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and THTR2 within the cancer microenvironment must be understood.  Therefore, our approach is to 
study the interaction of thiamine analogs that have high affinities for these two transport proteins.  
Using this strategy, we will investigate protein-thiamine analogs interactions and design analogs with 
higher affinities.   Furthermore, the study can also show the effect of hypoxia on SLC19A2 (THTR1) and 
SLC19A3 (THTR2) gene expression, translational and post-translational implications, and their 
functionality.  The understanding of the adaptive properties of the two thiamine transporters under low 
oxygen conditions is important. Without this knowledge, the understanding of how thiamine functions 
under hypoxic microenvironment cannot be fully understood.   
 
2 STRUCTURES DESIGN AND SYNTHESIS 
 
2.1 Structure Design and Discussion 
 The development of novel analogs of thiamine derivatives and investigating their binding 
properties to THTR1 and THTR2 begins by first, identifying different component of thiamine, second 
taking apart the structure and reconstructing different analogs.  Thiamine is composed of two rings: 
thiazol ring and pyrimidine ring.  The first step was to remove the five membered moiety, thiazol ring, 
and introduce a different five membered ring system into the structure.  We utilized the versatilities of 
“click chemistry” or 1,3 dipolar addition to introduce a different 5 member ring system by first 
introducing an azido group at this position. Second, the azido compound can react with a different 
alkynol to yield final analogs.  The reason for introducing the azido group at this position is due its ability 
to mimic the original structure.  The azido group allows us to maintain the five member ring moiety, and 
it also allows the nitrogen to be at the same position.   In designing this moiety, the changes that are 
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made to the analogs have to be subtle.  Changes that are too drastic may hinder the possibilities for 
interactions between the analogs and proteins.  Therefore, the azido group was introduced to this 
location.   
N
N
NH2
N+
S OH
N
N
NH2
N3
NaN3, Na2SO3
H2O
rt, 9 hrs
1 2  
Scheme 1:  First step is to remove the thiazol ring and replace it with an azido group. 
The reaction to make the azido compound 2 is fairly straight forward high yielding reaction.   The 
Reaction mechanism resembles an SN2, where azide acts as a nucleophile and "kicks" out the thiazol five 
member ring. 
N
N
NH2
N3 N
N
NH2
N
N N OHOH
t-BuOH, H2O
3
+
CuSO4
Sodium Ascorbate
rt, overnight
2  
Scheme 2:  Reaction of azido compound with 3-butyn-1-ol, to yield compound 3 with 51% yield. 
 From compound 2, we can synthesis of different thiamine analogs.  .  The first reaction was with 
3-butyn-1-ol yielded 51% of compounds 3.  All the reactions with different alkynols are examplesof 
Huisgen 1,3-dipolar cycloaddition,19 wherein there is an azido group reacting with an alkyne to form a 
five membered ring system.  The reaction occurred because of the π systems on both molecules.  All π 
electrons participate in a concerted, pericyclic shift; therefore, it is considered a stereoconservative 
addition.   
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[LnCu]
+
R' H
R' CuLn-1
N N
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N- R''
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N
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R''
N
N
N
R'
R''
A
B
C
D
C
R"
 
Figure 6:  General mechanism of the Click reaction, where there is a (3 + 2) cycloaddition similar to Diels-
Alder Reaction.20 
 The condition for the click reaction consists of 0.001 mmol of CuSO4 and 0.05 mmol of sodium 
ascorbate in 1:4 mixture of water:t-butanol mixture  Sodium ascorbate acts as a reducing agent to 
reduce Cu(II) to Cu(I).  Once the copper is reduced, the alkyne is then coordinated with copper to form 
intermediate A.  The azide then attacks the electron deficient copper to give intermediate B, where the 
azido group coordinates with the alkyne to form a six member intermediate ring C.  Finally, the 
intermediate rearranges into the five member ring and is hydrolyzed to give the product.18 
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N
N
NH2
N
N N
OHOH
4
t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
+
N
N
NH2
N3
2  
Scheme 3:  Reaction of azido compound with 3-butyn-2-ol to give compound 4. 
 The same conditions were applied to 3-butyn-2-ol to perform the click reaction.  The reaction 
was allowed to stir over night; however, this reaction did not go to completion.  Thin layer 
chromatography indicated that starting materials remained.  A second analog was formed in a 
reaction using compound 2and 4-pentyn-1-ol.  In this reaction, it follows the proposed mechanism with 
minimal interference.  The hydroxy group in this molecule is not close in proximity to the azido group; 
therefore, the chance of it acting as a nucleophile is minimal yielding 60% product 
N
N
NH2
N
N N
OHOH
5
t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
N
N
NH2
N3
2  
Scheme 4:  Reaction scheme between compound 2 and 4-pentyn-1-ol. 
 With three analogs in hand, all containing the pyrimidine, we set out to change the pyrimidine 
core into a pyridine.  In order to do this, we obtained 6-methyl-nicotinic acid, compound 6, from 
commercial source as starting material.  First, the carboxylic acid was converted into an ester with a 55% 
yield, compound 7.  The low yield resulted presumably due to water formation during the reaction 
process.  Initially, the reaction occurs rapidly because of the formation of water, however, once enough 
water is generated equilibrium is established, the reaction slows down.  Because water is a very good 
nucleophile, it can attack the carbonyl and reverse the compound back to starting materials. 
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N
OH
O
N
O
O
3 M HCl/MeOH
rt, overnight
6 7  
Scheme 5:  Reaction scheme showing the conversion of carboxylic acid into an ester, esterification. 
 The ester was then reduced to an alcohol via lithium aluminum hydride reductions.  Formation 
of the ester is necessary, because it allows lithium aluminum hydride to reduce it to an alcohol.  The 
reduction of carboxylic acid into an alcohol directly was difficult; instead, the hydride would acts as a 
base and deprotonate the proton on the acid and form an insoluble salt lithium salt.  The salt falls out of 
solution and thus results low yield. 
N
O
O
N
OHreflux, overnight
LiAlH4, THF
87  
Scheme 6:  Reduction of ester using lithium aluminum hydride. 
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N
O
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LiAlH4
Reflux, THF
12%
N
OH
N
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O
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N
O- Li+
O
N
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A 
N
O
O
H-
N
O
O-
H
N
H
O
N
H
O
H-
N
H
O-
H
N
OH
H+
 
B 
Figure 7:  A) Direct reduction of acid with lithium aluminum hydride mechanism.  B) Reduction of an 
ester using lithium aluminum hydride. 
N
OH
N
Cl
reflux, 2 hrs.
9
SOCl2, toluene
8  
Scheme 7:  Reaction scheme for converting alcohol into halide compound. 
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 Once compound 8 is obtained, it was reacted with thionyl chloride to give chloride compound 9.  
In this reaction, the hydroxyl is a very poor leaving group; therefore, it must first be activated by thionyl 
chloride.  The hydroxyl group is activated by attacking the thionyl and pushing a pair of electron out.  
Once the electrons pair fold back down it push out the chloride to form intermediate 1.  The chloride 
anion becomes a nucleophile and does a backside attacks on the alpha carbon to give product. 
 
Figure 8:  Proposed mechanism for converting alcohol into chloride compound.  In the reaction, there 
are two nucleophilic attacks. 
N
Cl
N
N31hr, 60oC
NaN3, DMF
109  
Scheme 8:  Reaction scheme for converting chloride compound into an azido compound, this is the last 
step before click chemistry. 
 The next step of the synthesis is to replace the halide with an azido group.  Azide is a very good 
nucleophile when it is in a polar solvent.  Therefore, DMF was used as solvent for the reaction.  The 
reaction occurs in a SN2 fashion, where the azide serves as the nucleophile attacking the alpha carbon 
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and displaced the chlorine to form inorganic salt with sodium.  When analyzing this compound, the H-
NMR spectrum of the product is very similar to the spectrum of starting material (compound 9).  IR was 
further used to confirm the presence of the azido group in the compound. 
 
 
Figure 9:  IR spectrum of azido compound (10). The azide functionality is seen at xxx wavenumber 
 Obtaining the azido compound 10, is the key step in the synthesis.  Compound 10 allows us to 
utilize click reaction to obtain additional analogs.   Once the azido compounds are obtained, click 
chemistry can then be applied with different alkynols.  The first alkynol that we used was 3-butyn-2-ol 
with a 45% yield of desired product.  2-Methyl-3-butyn-2-ol was used as the second alkynol with a 55% 
yield for desired product.  The last alkynol used was 3-butyn-1-ol with about 48% yield for desired 
product. 
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t-BuOH, H2O
rt, overnight
CuSO4
sodium ascorbate
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Scheme 9:Compound 10 was reacted with 3-butyn-2-ol, 2-methyl-3-butyn-2-ol and 3-butyn-1-ol to give 
three more analogs. 
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7 BIOLOGICAL STUDIES 
7.1 ANALOG EVALUATION   
 The synthesized analogs were evaluated and structure-analogs relationship was established.  
The evaluation was done by utilizing the Xenopus Oocyte transport systems.  Whole cell assay was done 
on four analogs and were tested against three controls; ifosfamide, fluorouracil (5-FU) and amiloride.  
Ifosfamide and 5-FU are both used to test for cyto-toxicity.  Amiloride specifically is used as a control for 
our inhibition property, because researches have shown that when amiloride is introduced into the cells 
it reduced thiamine concentration inside the cells.  In order to quantitatively keep track of how much 
thiamine is transported into the cells, radioactive thiamine was utilized and can be detecting by a 
scintillation counter.  By incubating the xenopus oocyte with radioactive thiamine and washing the 
reaction mixture to remove any access thiamine.  The cells were then spliced and measured for 
radioactivity and can be quantified.  According to the results, all of our analogs with the exception of 
one have comparable potency as amiloride.  Therefore, modification of the five member ring increased 
potency for therapeutics.  The results directed us toward the right direction and with more 
modifications more potent analogs can be made. 
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Figure 10: Four analogs were evaluated with for therapeutic potentials. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 Cancer is one of the most common causes of death in Americans, second to only heart disease.  
Although the main causes of cancer are still unknown, there are many studies designed to find a cure for 
cancer. Understanding how cancer works has been a progressive process.  One example of these 
endeavors is the research done on the HIF-1 protein to discover how it works. HIF-1 is a heterodimer 
that is composed of two subunits: an alpha and beta subunit.  Studies show that the formation of HIF-1 
protein can transcribe genes involved in glycolysis and angiogenesis.  Studies on how cancer cells 
operate and how they work are important to get a full picture of cancer.  In this approach, the aim is to 
understand the function of thiamine and how it is regulated in cancerous cells.  The first step in this 
approach is to synthesize a number of thiamine analogs and study their interactions with two known 
thiamine transporters: THTR1 and THTR2.  Our synthesized analogs were evaluated for their SAR utilizing 
the Xenopus Oocyte transport systems.  Analogs were compared with a known inhibitor amiloride and 
potency of the analogs was as equivalent to the known inhibitor.  Results indicated that with the 
modification of the five member ring was able to reduce the intake of thiamine approximately by half, 
which indicates that this position can be further modified for more potent analog.   
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EXPERIMENTAL 
 
 Thiamine (1) was obtained from VWR and was used directly without any purification.  Other 
starting materials were obtained from Aldrich, Acrosand Oakwood Chemicals.  1H and 13C spectra were 
obtained on a Bruker 400 NMR spectrometer in deuterated solvent with TMS as internal reference (δ = 
0.00 ppm).  For all reactions, analytical grade solvent were used.  Anhydrous solvents were used for all 
moisture-sensitive reactions.  FTIR spectrometer spectra were recorded on a PerkinElmer Spectrum 
Version 10.00.00 and only reported the significant band.  High resolution mass spectra were obtained 
with Waters Micromass Q-Tof (ESI).    
 
5-azidomethyl-2-methyl-pyrimidin-4-ylamine (2) 
N
N
NH2
N+
S OH
N
N
NH2
N3
NaN3, Na2SO3
H2O
rt, 9 hrs
1 2  
 In a 100 mL round bottom flask, 795 mg (3 mmol) of thiamine was dissolved in 30 mL of water 
and 497 mg (6 mmol) of NaN3 then 38 mg (0.3 mmol) of Na2SO3.  The reaction was allowed to stir for 9 
hours.  After 9 hours, the reaction was extracted with ethyl acetate(50mL x 3) then organic layers were 
combined and dried with sodium sulfate then concentrated using vacuo.  Product was purified using 
silica column chromatography with acetone:hexane (2:1) as solvent to give a  white solid (820 mg, 78%).  
1H NMR (400 MHz, CDCl3) δ ppm 8.09 (s, 1H), 5.31 (s, 2H), 4.24 (s, 2H), 2.54 (s, 3H).  
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2-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (3) 
N
N
NH2
N3 N
N
NH2
N
N N OHOH
t-BuOH, H2O
3
+
CuSO4
Sodium Ascorbate
rt, overnight
2  
 In a 100 mL round bottom flask, 85 mg (0.5 mmol) of 2was added with 36 mg (0.5 mmol) of 3-
butyn-1-ol in 5 ml of t-butanol (solution I).  In a 15 mL vial, 1 mg (5 µmol) of CuSO4 and 10 mg (0.05 
mmol) sodium ascorbic was dissolved in 1.0 mL of water (solution II).  Solution II was added to reaction 
flask drop wise via 1.0 mL syringe.  Reaction was allowed to stir overnight.  After overnight, the reaction 
was extracted with ethyl acetate three times (10mL) then organic layers were combined and dried over 
sodium sulfate and concentrated using vacuo.  Product was purified using silica column chromatography 
with 10:1 dichloromethane and methanol as mobile phase to give a white solid (43 mg, 51% yield).  1H 
NMR (400 MHz, CD3OD) δ ppm 8.05(s, 1H), 7.81 (s, 1H), 5.45 (s, 2H), 3.78 (t, J = 6.4 Hz, 2H), 2.89 (t, J = 
6.4 Hz,  2H), 2.41(s, 3H).  13C NMR (100 MHz, CD3OD) δ ppm:  167.5, 162.1, 155.1, 145.5, 122.7, 108.6, 
60.6, 28.5, 23.6.  HRMS (ESI):  Calculated for C10H15N6O[M+H]
+235.1307, found; 235.1311. 
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1-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (4) 
N
N
NH2
N
N N
OHOH
4
t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
+
N
N
NH2
N3
2  
 In a 100 mL round bottom flask, 60 mg (0.4 mmol) of compound 2 was added with 25 mg (0.4 
mmol) of 3-butyn-2-ol in 5 mL of t-butanol (solution I).  In a 15 mL vial, 1 mg (4 µmol) of CuSO4 and 7 mg 
(0.04 mmol) sodium ascorbic was dissolved in 1.0 mL of water (solution II).  Solution II was added to 
reaction flask drop wise with a 1.0 ml syringe.  Reaction was allowed to stir overnight.  After overnight, 
the reaction was extracted with ethyl acetate(10mL x 3) then organic layers were combined and dried 
over sodium sulfate and concentrated using vacuo.  Product was purified using silica column 
chromatography with 8:1 dichloromethane and methanol as mobile phase to give a white solid (31 mg, 
50% yield).  1H NMR (400 MHz, CD3OD) δ ppm 8.08(s, 1H), 7.92 (s, 1H), 5.51 (s, 2H), 4.99 (q, J = 6.4 Hz,  
1H), 2.43 (s, 3H), 1.54 (d, J = 6.4 Hz,  3H).  13C NMR (100 MHz, CD3OD) δ ppm 167.6, 162.1, 155.1, 152.9, 
121.3, 108.6, 62.2, 29.3, 23.6, 22.2.  HRMS (ESI):  Calculated for C10H14N6O [M+H]
+ 235.1307, found; 
235.1310. 
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3-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-1-ol (5) 
N
N
NH2
N
N N
OHOH
5
t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
N
N
NH2
N3
2  
 In a 100 mL round bottom flask, 64 mg (0.4 mmol) of compound 2 was added with 33 mg (0.4 
mmol) of 4-pentyn-1-ol in 5 mL of t-butanol (solution I).  In a 15 mL vial, 1 mg (4 µmol) of CuSO4 and 8 
mg (0.04 mmol) sodium ascorbic was dissolved in 1 mL of water (solution II).  Solution II was added to 
reaction flask drop wise via 1 mL syringe.  Reaction was allowed to stir overnight.  After overnight, the 
reaction was exacted with ethyl acetate(10mL x 3) then organic layers were collectedthen dried over 
sodium sulfate and concentrated using vacuo.  Product was purified using silica column chromatography 
with 6:1 dicholoromethane and methanol as mobile phase to give a white solid (40 mg, 63% yield).  1H 
NMR (400 MHz, CD3OD) δ ppm 8.03 (s, 1H), 7.77 (s, 1H), 5.45 (s, 2H), 3.57 (t, J = 6.4Hz, 2H), 2.75 (t, J = 
6.4Hz, 2H), 2.40 (s, 3H), 1.873-1.836 (m, 2H).  13C NMR (100 MHz, CD3OD) δ ppm 167.6, 162.1, 155.0, 
148.0, 122.0, 108.6, 60.5, 31.8, 23.7, 21.3.  HRMS (ESI):  Calculated forC11H17N6O [M+H]
+249.1464, 
found; 249.1470. 
 
6-Methyl-nicotinic acid methyl ester (7) 
N
OH
O
N
O
O
3 M HCl/MeOH
rt, overnight
6 7  
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 In a 500 mL round bottom flask, 3000 mg (21 mmol) of compound6 was dissolved in 30 mL of 
methanol and HCl solution and allowed to stir overnight.  After one night, the reaction solvent was 
removed using vacuo, and then dissolved in DCM.  DCM mixture was washed with water (50mL x 3) then 
dried over sodium sulfate and concentrated using vacuo.  Product was purified by silica column 
chromatography.  Dichloromethane and methanol (20:1 ratio) was used as mobile phase to 
giveclearclear oil (1530mg, 51%).  1H NMR (400 MHz, CDCl3) δ ppm 9.11 (d, J = 2Hz, 1H), 8.19 (dd, J = 2, 8 
Hz, 1H), 7.26 (t, J = 8.4Hz, 1H), 3.95 (s, 3H), 2.64 (s, 3H). 
 
 (6-Methyl-pyridin-3yl)-methanol (8) 
N
O
O
N
OHreflux, overnight
LiAlH4, THF
87  
 In a dried round bottom flask, 400.0 mg (3 mmol) of compound 7 was dissolved in 15.0 mL of 
dried THF and 182.16 mg (5 mmol) of lithium aluminum hydride was added last.  Reaction flask was 
equipped with a condenserunder argon and allowed to stir under reflux condition overnight.  Reaction 
was quenched by adding 20 ml of water and allowed it to stir for an additional 30 minutes.  Reaction 
was extracted after quenched with ethyl acetate(20 mL x 3) then organic layers were combined and 
driedoversodium sulfate then concentrated by vacuo.  Product was purified using silica column 
chromatography with dichloromethane and methanol (20:1 ratio) as mobile phase to give a golden oil 
(245mg, 61% yield).  1H NMR (400 MHz, CD3OD) δ ppm 8.30 (d, J = 1.6 Hz, 1H), 7.60 (dd, J =2.0, 8.0 Hz, 
1H), 7.11 (d, J = 8.0 Hz, 1H), 4.63 (s, 2H), 2.48 (s, 3H). 
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5-Chloromethyl-2-methyl-pyridine (9) 
N
OH
N
Cl
reflux, 2 hrs.
9
SOCl2, toluene
8  
 In a 100 mL round bottom flask,172.9 mg (1.4 mmol) of compound 8 was dissolved in 10.0 mL of 
toluene then thionyl chloride (1 mL, 5.6 mmol) was added in drop wise.  Reaction flask was then placed 
in an oil bath at 100oC, based on thin layer chromatography after two hours the reaction was done.  
Solvent was removed using vacuo, and the residue was dissolved in dichloromethane and washed with 
water (10mL x 3).  Organic layers were combined and dried over sodium sulfate then concentrated using 
vacuo.  Product was purified using silica column chromatography with ethyl acetate and hexane (10:1 
ratio) as the mobile phase to give a white solid (84mg, 49% yield).  1H NMR (400 MHz, CDCl3) δ ppm 8.48 
(s, 1H), 7.61 (dd, J =2.4, 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 4.55 (s, 2H), 2.55 (s, 3H). 
 
5-Azidomethyl-2-methyl-pyridine (10) 
N
Cl
N
N360oC, 1 hr
NaN3, DMF
109  
 In a 50 mL round bottom flask, 70.1 mg (0.5 mmol) of compound 9was dissolved in 5 mL of DMF, 
and then sodium azide (36 mg, 0.6 mmol) was added.  After one hour, thin layer chromatography 
showed the reaction was completed.  Reaction was quenched with water then extracted with ethyl 
acetate  (10mL x 3).  Organic layers were collected, dried over sodium sulfate, and concentrated using 
vacuo.  Product was purified using silica column chromatography with acetone and hexane (1:3 ratio) as 
the mobile phase to give a yellow oil (41mg, 58% yield).  1H NMR (400 MHz, CDCl3) δ ppm 8.431 (s, 1H), 
28 
 
7.53 (dd, J = 2.0, 8.0 Hz, 1H), 7.17 (d, J = 7.6 Hz, 1H), 4.316 (s, 2H), 2.55(s, 3H).  Vmax*cm
-1 2097.39 cm-
1(N3). 
 
1-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (11) 
N
N
N
N
HO
N
N3
OH
1110
t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
+
 
 In a 50 mL round bottom flask, 41 mg (0.3 mmol) of compound 10 was added with 2mg (0.3 
mmol) of 3-butyn-2-ol in 3 mL of t-butanol (solution I).  In a 15 mL vial,1 mg(3 µmol) of CuSO4 and 6 mg 
(0.03 mmol) sodium ascorbic was dissolved in 1 mL of water (solution II).  Solution II was added to 
reaction flask drop wise via 1 mL syringe.  Reaction was allowed to stir overnight.  After overnight, the 
reaction was extracted with ethyl acetate(10 mL x 3) then dried over sodium sulfate and concentrated 
using vacuo.  Product was purified using silica column chromatography with 10:1 dicholoromethan and 
methanol as mobile phase to give a white solid (21mg, 51% yield).  1H NMR (400 MHz, CDCl3) δ ppm 8.44 
(s, 1H), 7.50 (dd, J = 2, 8 Hz, 1H), 7.482 (s, 1H), 7.15 (d, J = 8 Hz,  1H), 5.47 (s, 2H), 5.05-5.03 (m, 1H), 3.18 
(s, 1H), 2.53 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ ppm 159.2, 153.3, 148.40, 
136.4, 127.5, 123.7, 120.1, 62.9, 51.3, 24.07, 23.2.  HRMS (ESI):  Calculated for:  C11H15N4O 
[M+H]+219.1246, found; 219.1247. 
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2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-2-ol (12) 
N
N
N
N
HO
N
N3
OH
12
+ t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
10  
 In a 50 mL round bottom flask, 30 mg (0.2 mmol) of compound 10 was added with 17 mg (0.2 
mmol) of 2-methyl-3-butyn-2-ol in 3 mL of t-butanol (solution I).  In a 15 ml vial,0.5 mg (2 µmol) of 
CuSO4 and 4 mg (0.02 mmol) sodium ascorbic was dissolved in 1 mL of water (solution II).  Solution II 
was added to reaction flask drop wise with 1 mL syringe.  Reaction was allowed to stir overnight.  After 
overnight, the reaction was extracted with with ethyl acetate (10 mL x 3) then organic layers were 
combined and dried over sodium sulfate then concentrated using vacuo.  Product was purified using 
silica column chromatography with 10:1 dichloromethane and methanol as mobile phase to give a white 
solid (9 mg, 30% yield).  1H NMR(400 MHz, CDCl3) δ ppm 8.46 (d, J = 2.0 Hz 1H), 7.51 (dd, J = 2.4, 8.0 Hz 
1H), 7.399 (s, 1H), 7.16 (d, J = 8.4 1H), 5.47 (s, 2H), 2.77 (s, 1H), 2.55 (s, 3H).  13C NMR (100 MHz, CDCl3) δ 
ppm:  159.6, 156.4, 148.5, 136.3, 127.5, 123.7, 119.0, 68.5, 51.3, 30.4, 24.1.  HRMS (ESI):  Calculated for:  
C12H17N4O [M+H]
+233.1402, found; 233.1394. 
 
2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4yl]-ethanol (13) 
N
N3
N
N
N
N
OH
OH
13
+ t-BuOH, H2O
CuSO4
Sodium Ascorbate
rt, overnight
10  
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 In a 50 mL round bottom flask, 35 mg (0.2 mmol) of compound 10 was added with 16.1 mg (0.2 
mmol) of 2-methyl-3-butyn-2-ol in 3 ml of t-butanol (solution I).  In a 15 ml vial,1 mg of CuSO4(2 µmol) 
and 5 mg (0.02 mmol) sodium ascorbic was dissolved in 1.0 mL of water (solution II).  Solution II was 
added to reaction flask drop wise via 1 ml syringe.  Reaction was allowed to stirredovernight.  After 
overnight, the reaction was extracted with ethyl acetate (10 mL x 3then organic layers were combined 
then dried over sodium sulfate and concentrated using vacuo.  Product was purified using silica column 
chromatography with 10:1 dichloromethane and methanol as mobile phase to give product (20 mg, 57% 
yield).  1H NMR (400 MHz, CDCl3) δ ppm 8.47 (d, J = 2.0 Hz 1H), 7.51 (dd, J = 2.0, 8.0 Hz,  1H), 7.36 (s, 1H), 
7.17 (d, J = 8.0 Hz 1H), 5.49 (s, 2H), 3.94 (t, J = 6.0 Hz,  2H), 2.93 (t, J = 6.0Hz,  2H), 2.562 (s, 3H).  13C NMR 
(100 MHz, CDCl3) δ ppm 159.3, 148.5, 146.3, 136.3, 123.7, 121.4, 61.5, 51.3, 28.7, 24.2.  HRMS (ESI):  
Calculated for:  C11H15N4O [M+H]
+219.1246, found; 219.1244. 
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APPENDICES 
The content of this appendix consist of NMR, mass spectrums and FTIR spectrum of the compounds 
which were synthesized and described above. 
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Figure 11:  5-azidomethyl-2-methyl-pyrimidin-4-ylamine (2)
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Figure 12:  2-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (3) H-NMR
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Figure 13:  2-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (3) C-NMR
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Figure 14:  2-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (3) mass. 
 
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
218 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 1-100    H: 1-100    N: 1-15    O: 1-20     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Calc. Mass mDa PPM DBE i-FIT Formula 
235.1311    235.1307        0.4       1.7       6.5       n/a         C10H15N6O 
 
100%MeOH+0.1%HCOOH 16:01:43  28-Mar-2012
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
HIEU_HDI35_BWANG-ACCU_03-27-2012_ESI-POS 158 (2.938) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (157:158)
1.73e3235.1311
621.3210
409.1743
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Figure 15:  1-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (4) H-NMR
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Figure 16:  1-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (4) C-NMR 
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Figure 17:  1-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (4) mass. 
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
218 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used:C: 1-100    H: 1-100    N: 1-15    O: 1-20     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Calc. Mass mDa PPM DBE i-FIT Formula 
235.1310 235.1307 0.3 1.3 6.5 7.7 C10H15N6O 
 
 
 
100%MeOH+0.1%HCOOH 15:49:38  28-Mar-2012
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
HIEU_HDI30_BWANG-ACCU_03-27-2012_ESI-POS 137 (2.556) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (134:141)
8.77e3235.1310
621.3170
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Figure 18:  3-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-1-ol (5) H-NMR
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Figure 19:  3-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-1-ol (5) C-NMR 
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Figure 20:  3-[1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-1-ol (5) mass 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
253 formula (e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used:C: 1-100    H: 1-100    N: 1-15    O: 1-20     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Cacl. Mass mDa PPM DBE i-FIT Formula 
249.1470    249.1464        0.6       2.4       6.5       4.2         C11H17N6O 
 
 
 
 
 
 
100%MeOH+0.1%HCOOH 15:56:11  28-Mar-2012
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
HIEU_HDI31_BWANG-ACCU_03-27-2012_ESI-POS 132 (2.452) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (129:137)
9.33e3249.1470
635.3355
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Figure 21:  6-Methyl-nicotinic acid methyl ester (7) 
 
43 
 
 
Figure 22:  (6-Methyl-pyridin-3yl)-methanol (8) 
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Figure 23:  5-Chloromethyl-2-methyl-pyridine (9) 
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Figure 24:  5-Azidomethyl-2-methyl-pyridine (10) 
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Figure 25:  IR of azido compound 10. 
 
47 
 
Figure26:  1-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (11) H-NMR
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Figure 27:  1-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (11) C-NMR 
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Figure 28:  1-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-ethanol (11) mass 
 
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
233 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 1-100    H: 1-100    N: 1-15    O: 1-20    Se: 0-2     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Calc. Mass mDa PPM DBE i-FIT Formula 
219.1247 219.1246 0.1 0.5 6.5 35.1 C11H15N4O 
 
 
100%MeOH+0.1%HCOOH 17:12:30  17-Apr-2012
m/z
150 200 250 300 350 400 450 500 550 600
%
0
100
HIEU_HD-I-98_BWANG-ACCU_04-17-2012_ESI-POS01 63 (1.171) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (55:69)
1.06e4219.1247
191.1188 556.2771
387.1859255.1344 339.1477 605.3005
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Figure 29:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-2-ol (12) H-NMR
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Figure 30:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-2-ol (12) C-NMR 
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Figure 31:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4-yl]-propan-2-ol (12) mass 
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
281 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 1-100    H: 1-100    N: 1-15    O: 1-20    Se: 0-2     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Calc. Mass mDa PPM DBE i-FIT Formula 
233.1394 233.1402 -0.8 -3.4 6.5 1.2 C12H17N4O 
 
 
 
100%MeOH+0.1%HCOOH 17:08:58  17-Apr-2012
m/z
150 200 250 300 350 400 450 500 550 600
%
0
100
HIEU_HD-I-80_BWANG-ACCU_04-17-2012_ESI-POS01 75 (1.390) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (72:76)
4.65e3233.1394
187.1247 255.1216
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Figure 32:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4yl]-ethanol (13) H-NMR
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Figure 33:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4yl]-ethanol (13) C-NMR 
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Figure 34:  2-[1-(6-methyl-pyridin-3-ylmethyl)-1H-[1,2,3]triazol-4yl]-ethanol (13) mass 
 
Elemental Composition Report 
Single Mass Analysis 
Tolerance = 5.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
Monoisotopic Mass, Even Electron Ions 
233 formula(e) evaluated with 1 results within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 1-100    H: 1-100    N: 1-15    O: 1-20    Se: 0-2     
Minimum:       -1.5 
Maximum:     5.0       5.0       50.0 
Mass Cacl. Mass mDa PPM DBE i-FIT Formula 
219.1244 219.1246 -0.2 -0.9 6.5 4.9 C11H15N4O 
 
 
100%MeOH+0.1%HCOOH 17:03:17  17-Apr-2012
m/z
100 200 300 400 500 600 700 800 900 1000
%
0
100
HIEU_HD-I-82_BWANG-ACCU_04-17-2012_ESI-POS01 79 (1.473) AM (Cen,4, 80.00, Ar,5000.0,556.28,0.70); Cm (71:80)
8.84e3219.1244
